Objective: This study aims to understand the adverse drug reactions (ADRs) for non-statin antihyperlipidaemic drugs included in the China Anti-hyperlipidemic Drug Database.
Design: An approach of Chinese national database analysis was employed to screen clinical trials involving non-statin antihyperlipidaemic drugs from 1989 to 2019.
Setting: The database was provided by the China National Medical Products Administration Information Centre.
Participants: In total, 117 clinical studies with 8800 patients were selected from 2650 clinical trials of the Anti-hyperlipidemic Drug Database.
Interventions: The non-statin antihyperlipidaemic drugs were divided into three groups: (1) fibrates (fenofibrate, gemfibrozil, bezafibrate, etofylline clofibrate); (2) nicotinic acid and derivatives (niacin, acipimox) and (3) others (probucol, cholestyramine).
Results: The results of this study show that first, gastrointestinal symptoms were the most common reactions (6.975%), which account for approximately 50% of the reported cases with ADRs. Second, cholestyramine (16.418%) and gemfibrozil (13.158%) were the most common gastrointestinal side effect-causing non-statin antihyperlipidaemic drugs, which account for one-third of the population. Third, niacin (7.879%) and gemfibrozil (5.000%) were the most likely cause of liver disease symptoms. Finally, niacin (10.909%) and acipimox (18.847%) were the major non-statin antihyperlipidaemic drugs with skin symptoms.
Conclusion: This study revealed that gastrointestinal symptoms were the most common ADRs of fibrates, probucol and cholestyramine in the Chinese population. For nicotinic acid and derivatives, the ADRs of skin symptoms were the most common in China.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254877 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2022-068915 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Sarcopenia Following Long-Term Statin Use in Community-Dwelling Middle-Aged and Older Adults in Japan.
J Cachexia Sarcopenia Muscle
February 2025
Department of Epidemiology of Aging, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Background: Inconsistent results have been reported concerning the association between statin administration and muscle health, specifically its potential to increase the risk of sarcopenia. Given the widespread long-term use of statins among the elderly population, the exploration of this association remains a crucial yet insufficiently examined matter. This study aimed to assess the association between the prolonged administration of statins and the risk of sarcopenia, diminished muscle strength, reduced skeletal muscle mass and impaired physical performance.
View Article and Find Full Text PDFStatin-Associated Muscle Symptoms: Identification and Recommendations for Management.
Curr Atheroscler Rep
November 2024
Emory Department of Medicine, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory University, Atlanta, GA, USA.
Article Synopsis
- Statins are the primary medication for lowering bad cholesterol (LDL), but some patients experience muscle-related side effects known as statin-associated muscle symptoms (SAMS).
- Recent guidelines from organizations like the National Lipid Association provide strategies for doctors to identify and manage patients with SAMS, as this is the most common reason for statin intolerance.
- Many patients can still tolerate some statin therapy, and when combined with non-statin medications, an effective treatment plan can be created through open discussions between clinicians and patients to lower the risk of heart disease.
Effect of statin on long-term outcomes in persistent tobacco users receiving percutaneous coronary intervention: A longitudinal, retrospective cohort study.
Medicine (Baltimore)
November 2024
Department of Pediatrics, Chang-Gung Medical Foundation Chiayi, Chang-Gung Memorial Hospital, Chiayi County, Taiwan.
The role of statins in improving cardiovascular outcomes is well established, but little is known about their impacts on long-term outcomes in persistent tobacco users with stable coronary artery disease (CAD) who receive percutaneous coronary intervention (PCI). A population of persistent smokers with CAD treated by PCI was analyzed. From 2012 through 2019, a cohort of 907 persistent tobacco users with stable CAD undergoing PCI were enrolled from the inpatient department of Taichung Tzu Chi Hospital, Taiwan.
View Article and Find Full Text PDFAssessment of bleeding events in patients receiving DOACs with or without statins to treat venous thromboembolism: insights from the RIETE registry.
BMJ Open
October 2024
Universidad Católica de Murcia, Murcia, Spain.
Objective: To evaluate the impact of coadministering statins with direct oral anticoagulants (DOACs) on the risk of major bleeding events in patients with venous thromboembolism (VTE).
Design: Observational cohort analysis based on a multicentre international registry.
Setting: Data were extracted from the Registro Informatizado de Enfermedad TromboEmbolica Registry, which involves 205 centres across 27 countries.
Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence.
Prim Care Diabetes
December 2024
Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK. Electronic address:
Article Synopsis
- A systematic review and meta-analysis was conducted to determine if baseline use of statins affects the cardiovascular and kidney benefits of two diabetes medications: SGLT-2 inhibitors and GLP-1 receptor agonists.
- The analysis included 25 studies, revealing that both SGLT-2is and GLP-1RAs provided similar benefits in reducing cardiovascular and kidney risks in patients with type 2 diabetes, regardless of whether they were statin users or non-users.
- The findings suggest that statin use does not significantly impact the effectiveness of these medications in improving cardiovascular and kidney outcomes for patients with type 2 diabetes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!